PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test
At DNA Labs UAE, we offer the PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test for the diagnosis and management of acute promyelocytic leukemia (APL). This test detects the presence and quantifies the level of a specific gene rearrangement called PML-RARA.
Test Details
The PML-RARA t(15;17)(q22;q12) gene rearrangement quantitative PCR (polymerase chain reaction) test is a diagnostic test used to detect the presence and quantify the level of a specific gene rearrangement called PML-RARA. This rearrangement is characteristic of a specific type of leukemia called acute promyelocytic leukemia (APL). APL is a subtype of acute myeloid leukemia (AML) that is characterized by the fusion of two genes: the promyelocytic leukemia (PML) gene on chromosome 15 and the retinoic acid receptor alpha (RARA) gene on chromosome 17. This fusion gene, PML-RARA, plays a crucial role in the development of APL.
The quantitative PCR test is performed on a blood or bone marrow sample from a patient suspected to have APL. It measures the amount of PML-RARA fusion gene in the sample, which can provide information about the disease burden and response to treatment. The test is highly sensitive and can detect even very low levels of PML-RARA. The results of the quantitative PCR test are reported as a numerical value, indicating the level of PML-RARA gene expression.
Test Cost
The cost of the PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test is 1220.0 AED.
Symptoms and Diagnosis
Common symptoms of APL include fatigue, shortness of breath, frequent infections, bleeding, and bruising. If you are experiencing these symptoms or if your doctor suspects APL based on your medical history and physical examination, they may recommend the PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test to confirm the diagnosis.
Referring Details
To perform the test, we require a 5 mL (3 mL min.) whole blood sample from 2 Lavender Top (EDTA) tubes. The sample should be shipped refrigerated and should not be frozen. Additionally, a duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.
Report Delivery
The sample for the PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test should be submitted on Monday, Wednesday, or Friday by 9 am. The test report will be delivered on Tuesday, Thursday, or Saturday.
Test Type
The PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test falls under the category of Leukemia tests.
Doctor and Test Department
This test is typically ordered by an Oncologist and is performed in our Molecular Diagnostics department.
Pre Test Information
A duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory before performing the PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test.
Conclusion
The PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test is an important tool in the diagnosis, monitoring, and management of APL patients. It provides valuable information about the disease status and guides treatment decisions. If you suspect APL or have been diagnosed with APL, consult with your doctor about the possibility of undergoing this test.
Test Name | PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE PCR Test |
---|---|
Components | |
Price | 1220.0 AED |
Sample Condition | 5 mL (3 mL min.)wholebloodfrom2 LavenderTop(EDTA)tubes. Ship refrigerated. DO NOT FREEZE. Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. |
Report Delivery | SampleMon/Wed / Fri by 9 am;Report Tue / Thu / Sat |
Method | Real Time PCR |
Test type | Leukemia |
Doctor | Oncologist |
Test Department: | MOLECULAR DIAGNOSTICS |
Pre Test Information | Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. |
Test Details |
The PML-RARA t(15;17)(q22;q12) gene rearrangement quantitative PCR (polymerase chain reaction) test is a diagnostic test used to detect the presence and quantify the level of a specific gene rearrangement called PML-RARA. This rearrangement is characteristic of a specific type of leukemia called acute promyelocytic leukemia (APL). APL is a subtype of acute myeloid leukemia (AML) that is characterized by the fusion of two genes: the promyelocytic leukemia (PML) gene on chromosome 15 and the retinoic acid receptor alpha (RARA) gene on chromosome 17. This fusion gene, PML-RARA, plays a crucial role in the development of APL. The quantitative PCR test is performed on a blood or bone marrow sample from a patient suspected to have APL. It measures the amount of PML-RARA fusion gene in the sample, which can provide information about the disease burden and response to treatment. The test is highly sensitive and can detect even very low levels of PML-RARA. The results of the quantitative PCR test are reported as a numerical value, indicating the level of PML-RARA gene expression. Monitoring the levels of PML-RARA during and after treatment can help assess the effectiveness of therapy and detect any relapse or residual disease. This test is an important tool in the diagnosis, monitoring, and management of APL patients, as it provides valuable information about the disease status and guides treatment decisions. |